Experience of combined topical therapy with methylprednisoloni aceponatis and «Bepanten Plus»® in treatment of adult patients with moderate and severe atopic dermatitis
- Authors: Shtyrbul OK1, Erina OA1, Fedenko ES1
-
Affiliations:
- Institute of Immunology
- Issue: Vol 12, No 6 (2015)
- Pages: 80-83
- Section: Articles
- URL: https://journals.rcsi.science/raj/article/view/120775
- DOI: https://doi.org/10.36691/RJA410
- ID: 120775
Cite item
Open Access
Access granted
Subscription Access
Abstract
Background. To estimate efficiency of combined therapy with methylprednisolone aceponatis and «Bepanten Plus»® in adult patients with moderate and severe atopic dermatitis. Methods. We examined 32 adult patients, who were treated with TGCS methylprednisolone aceponatis and «Bepanten Plus»®. The efficiency of therapy was estimated with index SCORAD, IGA and subjective patients assessment. For 15 of 32 patients swabs for bacterial isolation to estimate Staphylococcus aureus growth were taken from lesional skin before therapy and on the 14 th or 20 th days of treatment. Results. The аverage value of index SCORAD decreased after 15 days of therapy, Me 41,7 to Me 23,3 a point (p<0,01), Investigated Global Assessment mediana decreased from 2 to 1 (p<0,01). The colonization density of S. aureus more than 10 3 CFU/cm 2 in all 15 patients before treatment and only in 3 patients in 14-20 days after the treatment was found. Conclusion. Clinical efficiency of «Bepanten Plus»® in combined therapy with methylprednisolone atseponat and its antiseptic action at AD patients has shown.
Full Text
##article.viewOnOriginalSite##About the authors
O K Shtyrbul
Institute of ImmunologyMoscow, Russia
O A Erina
Institute of ImmunologyMoscow, Russia
E S Fedenko
Institute of ImmunologyMoscow, Russia
References
- Hanifin J.M. Atopic dermatitis: broadening the perspective. J. Am. Acad. Dermatol. 2004, v. 51, p. 23-24.
- Leung D.YM. Role of Staphylococcus aureus in atopic dermatitis. Atopic dermatitis edited by Bieber T, Leung D.Y. M., Marcel-Dekker, Inc. New-York-Basil. 2002, p. 401-418.
- Breuer K., Kapp A., Werfel T Bacterial infections and atopic dermatitis. Allergy. 2001, v. 56, p. 1034-1041.
- Bunikowski R., Mielke M.E., Skarabis H., Worm M. et al. Evidence for a disease promoting effect of Staphylococcus aureus derived exotoxins in atopic dermatitis. J. Allergy Clin. Immunol. 2000, v. 105, p. 814-819.
- Ring J., Alomar A., Bieber T, Deleuran M., Fink-Wagner L. et al. Guidelines for treatment of atopic eczema (atopic dermatitis). Part I. J. Eur. Acad. Dermatol. Venereol. 2012, v. 26, p. 1045-1060.
- Johnson S.M., Kincannon J.M., Dudney D.L. Arkansas Foundation for Medical Care. Topical treatment for atopic dermatitis in the 21st century. J. Ark. Med. Soc. 2004, v. 101, p. 86-90.
- Ebner F., Heller A., Rippke F., Tausch I. Topical use of dex-panthenol in skin disorders. Am. J. Clin. Dermatol. 2002, р. 427-433.
- Biro K., Thaci D., Ochsendorf F.R. et al. Efficacy of dexpan-thenol in skin protection against irritation: a double-blind, placebo-controlled study. Contact Dermatitis. 2003, v. 49, р. 80-84.
- Hanifin J.M., Rajka G. Diagnostic features of atopic dermatitis. Acta Dermato-Venereologica.1980, v 92, р. 44-47.
